233 related articles for article (PubMed ID: 33612078)
1. Prediction of the Therapeutic Effects of Pembrolizumab and Nivolumab in Advanced Non-Small Cell Lung Cancer by Platelet-Derived Microparticles in Circulating Blood.
Liu T; Wang J; Liu Y; Wu J; Yuan Y; Wang C; Fang X; Li H
Technol Cancer Res Treat; 2021; 20():1533033821997817. PubMed ID: 33612078
[TBL] [Abstract][Full Text] [Related]
2. Predicting disease progression in advanced non-small cell lung cancer with circulating neutrophil-derived and platelet-derived microparticles.
Liu T; Wang J; Li T; Cui P; Hou B; Zhuang C; Wei G; Zhang S; Li H; Hu Y
BMC Cancer; 2021 Aug; 21(1):939. PubMed ID: 34416874
[TBL] [Abstract][Full Text] [Related]
3. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
4. Validation of a clinical blood-based decision aid to guide immunotherapy treatment in patients with non-small cell lung cancer.
Muller M; Hoogendoorn R; Moritz RJG; van der Noort V; Lanfermeijer M; Korse CM; van den Broek D; Ten Hoeve JJ; Baas P; van Rossum HH; van den Heuvel MM
Tumour Biol; 2021; 43(1):115-127. PubMed ID: 34219680
[TBL] [Abstract][Full Text] [Related]
5. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer.
Komiya K; Nakamura T; Abe T; Ogusu S; Nakashima C; Takahashi K; Kimura S; Sueoka-Aragane N
Thorac Cancer; 2019 Sep; 10(9):1798-1804. PubMed ID: 31328416
[TBL] [Abstract][Full Text] [Related]
6. Impact of concomitant medication on clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: A retrospective study.
Miura K; Sano Y; Niho S; Kawasumi K; Mochizuki N; Yoh K; Matsumoto S; Zenke Y; Ikeda T; Nosaki K; Kirita K; Udagawa H; Goto K; Kawasaki T; Hanada K
Thorac Cancer; 2021 Jul; 12(13):1983-1994. PubMed ID: 33990133
[TBL] [Abstract][Full Text] [Related]
7. Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath.
de Vries R; Muller M; van der Noort V; Theelen WSME; Schouten RD; Hummelink K; Muller SH; Wolf-Lansdorf M; Dagelet JWF; Monkhorst K; Maitland-van der Zee AH; Baas P; Sterk PJ; van den Heuvel MM
Ann Oncol; 2019 Oct; 30(10):1660-1666. PubMed ID: 31529107
[TBL] [Abstract][Full Text] [Related]
8. Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC).
Ricciuti B; Jones G; Severgnini M; Alessi JV; Recondo G; Lawrence M; Forshew T; Lydon C; Nishino M; Cheng M; Awad M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771889
[TBL] [Abstract][Full Text] [Related]
9. Time courses and value of circulating microparticles in patients with operable stage non-small cell lung cancer undergoing surgical intervention.
Tseng CC; Wang CC; Hsiao CC; Lu HI; Leu S; Chang HC; Huang KT; Fang WF; Chen YM; Liu SF; Yang CT; Lin MC; Yip HK
Tumour Biol; 2016 Sep; 37(9):11873-11882. PubMed ID: 27059732
[TBL] [Abstract][Full Text] [Related]
10. Circulating endothelial cells and microparticles for prediction of tumor progression and outcomes in advanced non-small cell lung cancer.
Najjar F; Alammar M; Al-Massarani G; Almalla N; Aljapawe A; Ikhtiar A
Cancer Biomark; 2017 Sep; 20(3):333-343. PubMed ID: 28800312
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of subsequent docetaxel +/- ramucirumab and S-1 after nivolumab for patients with advanced non-small cell lung cancer.
Tamura N; Horinouchi H; Sekine K; Matsumoto Y; Murakami S; Goto Y; Kanda S; Fujiwara Y; Yamamoto N; Ohe Y
Thorac Cancer; 2019 May; 10(5):1141-1148. PubMed ID: 30913364
[TBL] [Abstract][Full Text] [Related]
12. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R
JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354
[TBL] [Abstract][Full Text] [Related]
14. Real-world comparison of immune checkpoint inhibitors in non-small cell lung cancer following platinum-based chemotherapy.
Weis TM; Hough S; Reddy HG; Daignault-Newton S; Kalemkerian GP
J Oncol Pharm Pract; 2020 Apr; 26(3):564-571. PubMed ID: 31238808
[TBL] [Abstract][Full Text] [Related]
15. Circulating endothelial-derived activated microparticle: a useful biomarker for predicting one-year mortality in patients with advanced non-small cell lung cancer.
Wang CC; Tseng CC; Hsiao CC; Chang HC; Chang LT; Fang WF; Leu S; Wang YH; Tsai TH; Yang CT; Chen CH; Yip HK; Ho CK; Lin MC
Biomed Res Int; 2014; 2014():173401. PubMed ID: 25061601
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer.
Yamaguchi O; Imai H; Minemura H; Suzuki K; Wasamoto S; Umeda Y; Osaki T; Kasahara N; Uchino J; Sugiyama T; Ishihara S; Ishii H; Naruse I; Mori K; Kotake M; Kanazawa K; Minato K; Kagamu H; Kaira K
Cancer Chemother Pharmacol; 2020 Apr; 85(4):761-771. PubMed ID: 32193618
[TBL] [Abstract][Full Text] [Related]
17. Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.
Yan Y; Wang X; Liu C; Jia J
BMC Pulm Med; 2022 Apr; 22(1):166. PubMed ID: 35484541
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
Zhang N; Jiang J; Tang S; Sun G
Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
[TBL] [Abstract][Full Text] [Related]
20. Do systemic treatments delivered after Nivolumab result in better outcomes? A bicentric case-control study.
Darrason M; Chatelain E; Ranchon F; Gervaise C; Duruisseaux M; Couraud S
Respir Med Res; 2020 Mar; 77():100-105. PubMed ID: 32512522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
